Bristol Myers Squibb’s (NYSE: BMY) immuno-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to deliver mixed results, according to data shared at the European Society for Medical Oncology (ESMO) Congress 2021.
The combination could offer a benefit as a first-line treatment for patients with squamous head and neck cancer who express high levels of PD-L1, full data from the Checkmate-651 study show.
Checkmate-651 was in fact a failed trial, with the regimen not delivering a benefit in general as a first-line option, though the full results presented as ESMO show benefit in these patients with high PD-L1 levels.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze